*
*Glaucoma|23986001
*
*
is
an eye disease|371405004
in which
the optic nerve|18234004|180938001
is
damaged|37782003
in a characteristic pattern.|272135003

This
can
permanently
damage|37782003
vision|281004000
in the affected eye|247591002|81745001|247591002|244486005|248448006|81745001|248448006|244486005
(s)
and
lead|88488004
to blindness
if
left|7771000
untreated.|25265005

It
is
normally
associated|47429007
with increased fluid pressure|13066001
in the eye|81745001|244486005
(aqueous humour.|425460003|280587006

The term "ocular hypertension"|4210003
is
used|394850002
for people|125676002
with consistently
raised|260399008
intraocular pressure (IOP)|41633001|252832004|370960006
without any associated optic nerve damage.|47429007|18234004|37782003|47429007|180938001|37782003|47429007|81745001|57182000

Conversely,
the term 'normal tension'|17621005|53489000|258744000|53489000
or
'low tension' glaucoma|50485007
is
used|394850002
for those with optic nerve damage|20401003|18234004|37782003|20401003|180938001|37782003|20401003|81745001|57182000|421463005|18234004|37782003|421463005|180938001|37782003|421463005|81745001|57182000
and
associated visual field loss,|47429007|23388006
but
normal|17621005|258744000
or
low IOP.|62482003|371880002

The nerve damage|57182000
involves|248448006
loss
of retinal ganglion cells|5665001|53102003|103067001|53102003
in a characteristic pattern.|272135003

The many different subtypes|260396001|263735002|260837004
of glaucoma|23986001
can
all
be
considered
to
be
a type|261664005
of optic neuropathy.|77157004

Raised intraocular pressure|112222000
(
above 21 mmHg|304621005
or
2.8 kPa|260306008|259017006
)
is
the most important|4757001
and
only modifiable risk factor|50607009|80943009|420295001|80943009
for glaucoma.|23986001

However,
some
may
have
high eye pressure|75540009|81745001|279046003|75540009|81745001|13543005|75540009|81745001|257893003|75540009|244486005|279046003|75540009|244486005|13543005|75540009|244486005|257893003|371879000|81745001|279046003|371879000|81745001|13543005|371879000|81745001|257893003|371879000|244486005|279046003|371879000|244486005|13543005|371879000|244486005|257893003
for years|258707000
and
never
develop
damage,|37782003
while
others|74964007
can
develop
nerve damage|57182000
at a relatively low pressure.|62482003|279046003|62482003|13543005|62482003|257893003|371880002|279046003|371880002|13543005|371880002|257893003

Untreated glaucoma|25265005|23986001
can
lead|88488004
to permanent damage|6934004|37782003
of the optic nerve|18234004|180938001
and
resultant visual field loss,|23388006
which over time|21481007|410669006
can
progress|385651009
to blindness.

Glaucoma|23986001
can
be
roughly
divided|422033008
into two main categories,|420797005|63161005
"
open-|56116003
angle"|1483009
and
"
closed-|29179001
angle"|1483009
(
or
"angle closure") glaucoma.|392291006

The angle refers|1483009|439980006
to the area|42798000
between the iris|41296002|27527003|181164000
and
cornea,|28726007|181162001
through which fluid|32457005|33463005|255765007
must
flow to
escape
via the trabecular meshwork.|66731004|280694002

Closed-angle glaucoma|392291006
can
appear
suddenly
and
is
often painful|70232002|22253000
;
visual loss|397540003
can
progress|385651009
quickly,
but
the discomfort often|367391008|70232002|87128005|70232002
leads|88488004|236874000
patients to|116154003
seek
medical attention|74188005|6769007
before permanent damage|6934004|37782003
occurs.|272120004

Open-|56116003
angle,|1483009
chronic glaucoma|90734009|23986001
tends
to
progress|385651009
at a slower rate|419443000
and
patients|116154003
may
not notice
they
have
lost vision|281004000
until the disease|64572001
has
progressed|385651009
significantly.

Glaucoma|23986001
has
been
called
the "silent thief|263872000|248027001|263872000|105557001
of sight"|281004000
because
the loss
of vision often|281004000|70232002
occurs|272120004
gradually
over a long period|255511005|259037005
of time,|410669006
and
symptoms only
occur|272120004
when
the disease|64572001
is
quite
advanced.|86005002

Once
lost
,
vision|281004000
cannot
normally
be
recovered|74822006
,
so
treatment|276239002|416118004
is
aimed
at preventing further loss.|46053002|116699007|46053002

Worldwide,
glaucoma|23986001
is
the second-leading cause|81170007|236874000|134198009|257997001|236874000|134198009|288495006|236874000|134198009
of blindness after cataracts.|47337003

It
is
also
the leading cause|236874000|134198009
of blindness
among African Americans.|15086000

Glaucoma|23986001
affects|4065008
one|421379005
in 200 people|125676002
aged|424144002|105436006
50
and
younger,|84422007
and
one|421379005
in 10
over the age|424144002
of eighty.

If
the condition|260905004
is
detected early enough,|260373001|264499004
it
is
possible to|371930009|60022001
arrest|397829000|6155003
the development|278923009
or
slow|419443000
the progression|246453008|246450006
with medical|74188005
and
surgical means.|83578000|255586005

Screening|20135006
for glaucoma|23986001
in the general population|60132005|385436007|60132005|389109008
is
however
unsupported
by the evidence.|18669006

The word "glaucoma"|255373000|23986001
comes
from the Greek ????????,|1451003
"opacity|125149003|128305008
of the crystalline lens".|78076003

(Cataracts|247053007|95722004
and
glaucoma|23986001
were
not
distinguished
until
_circa_ 1705
).[4]|260308009

The two main types|420797005|63161005|261664005
of glaucoma|23986001
are
open-angle glaucoma|46168003
and
closed-angle glaucoma|392291006
(also called angle closure glaucoma|392291006
).

Open-angle glaucoma|46168003
accounts
for 90%|264705001|264703008
of glaucoma cases|23986001|398241000|23986001|413769002
in the United States.|223688001

It
is
painless|255350008
and
does
not
have
acute attacks.|272118002|216299002

The only signs|50607009|72670004|420295001|72670004
are
gradually progressive visual field loss,|255314001|23388006
and
optic nerve changes|18234004|243326001|18234004|263703002|180938001|243326001|180938001|263703002
(increased cup-to-disc ratio|35105006|415183006|118586006|35105006|428178003|118586006|260366006|415183006|118586006|260366006|428178003|118586006
on fundoscopic examination|53524009|5880005
).

Closed-angle glaucoma|392291006
accounts
for less|276139006|263796003
than 10%
of glaucoma cases|23986001|398241000|23986001|413769002
in the United States,|223688001
but
as many|260396001
as half
of glaucoma cases|23986001|398241000|23986001|413769002
in other nations|74964007
(particularly Asian countries|223571003
).

About 10%
of patients|116154003
with closed angles|251726002
present|52101004|246105001
with acute angle closure crises|272118002|251726002|32937002
characterized
by sudden ocular pain,|255363002|41652007
seeing|281004000
halos|83551002
around lights,|56242006
red eye,|75705005
very high intraocular pressure|260358002|112222000
(
>30 mmHg|304621005
)
,
nausea|422587007
and
vomiting,|249497008
suddenly decreased vision,|397540003|225581002
and
a fixed, mid-dilated pupil.|102491009|37125009|261010008|37125009

It
is
also
associated|47429007
with an oval pupil|392406005|35146001
in some cases.|398241000|413769002

Acute angle closure|272118002|251726002
is
an emergency.|25876001

Of the several causes|261028005|134198009
for glaucoma,|23986001
ocular hypertension|4210003
(increased pressure|51590001
within the eye|81745001|244486005
)
is
the most important risk factor|4757001|80943009
in most glaucomas,|23986001
but
in some populations,|385436007
only 50%|50607009|420295001
of people|125676002
with primary open-angle glaucoma actually|77075001
have
elevated ocular pressure.[5]|75540009|81745001|279046003|75540009|81745001|13543005|75540009|81745001|257893003|75540009|281004000|279046003|75540009|281004000|13543005|75540009|281004000|257893003|75540009|279046003|75540009|13543005|75540009|257893003

No clear evidence|263707001|18669006
indicates|410535002
vitamin deficiencies|85670002
cause|23981006|134198009
glaucoma|23986001
in humans.|278412004

It
follows|367409002
,
then,
that oral vitamin supplementation|260548002|226314006
is
not
a recommended treatment|276239002|416118004
for glaucoma.|23986001

Caffeine|255641001
increases|260366006
intraocular pressure|41633001|252832004|370960006
in those with glaucoma,|20401003|23986001|421463005|23986001
but
does
not
appear
to
affect|4065008
normal individuals.[7]|17621005|125676002|17621005|385435006|258744000|125676002|258744000|385435006

Many people|260396001|125676002
of East Asian descent|414978006
are
prone|1240000
to developing angle closure glaucoma|392291006
due to shallower anterior chamber depths,|363948008
with the majority
of cases|398241000|413769002
of glaucoma|23986001
in this population|385436007|389109008
consisting
of some form|246176004
of angle closure.|251726002

Inuit
also
have
a 20
to 40 times|259031006|410669006|259031006|417929005
higher risk|15508007
of developing primary angle closure glaucoma.|392291006|392288006

Women|224526002
are
three times more likely|421291004|410669006|2931005|421291004|417929005|2931005
than men to|339947000
develop
acute angle closure glaucoma|30041005
due to their shallower anterior chambers.|31636006

People|125676002
of African descent|413464008
are
three times more likely to|421291004|410669006|2931005|421291004|417929005|2931005
develop
primary open angle glaucoma.|77075001

Various rare congenital/genetic eye malformations|256220008|84638005|204821009|81745001|256220008|84638005|204821009|244486005|256220008|103356009|204821009|81745001|256220008|103356009|204821009|244486005
are
associated|47429007
with glaucoma.|23986001

Occasionally,
failure|76797004
of the normal third trimester gestational atrophy|17621005|255248002|255402008|13331008|258744000|255248002|255402008|13331008
of the hyaloid canal|19359003
and
the tunica vasculosa lentis|343416008
is
associated|47429007
with other anomalies.|74964007

Angle closure-induced ocular hypertension|251726002|16404004|4210003
and
glaucomatous optic neuropathy|23986001|77157004
may
also
occur|272120004
with these anomalies.

and
modelled
in mice.|447612001|447482001

Primary open angle glaucoma (POAG)|77075001
has
been
found|404684003
to
be
associated|47429007
with mutations|55446002
in genes|67271001
at several loci.|261028005

Normal tension glaucoma,|50485007
which
comprises
one-third|421379005|70905002
of POAG,|77075001
is
associated|47429007
with genetic mutations.|55446002

People|125676002
with a family history|57177007
of glaucoma|23986001
have
about six percent chance|422218008|118582008
of developing glaucoma.|23986001

Other factors|74964007
can
cause|23981006|134198009
glaucoma,|23986001
known|36692007
as "secondary glaucomas",|95717004
including|55919000
prolonged use|255224006|277889008|255224006|419385000
of steroids|116566001
(steroid-induced glaucoma|116566001|16404004|23986001
)
;
conditions|78326006|260905004
that severely|24484000
restrict|263856008
blood flow|58190003
to the eye,|81745001|244486005
such as severe diabetic retinopathy|24484000|4855003
and
central retinal vein occlusion|68478007
(neovascular glaucoma|232086000
)
;
ocular trauma|81745001|81745001|281004000|281004000
(angle recession glaucoma|392352004
)
;
and
uveitis|128473001
(uveitic glaucoma|314033007
).

In a large study|255509001|110465008|255509001|224699009
in the UK,
glaucoma patients|23986001|116154003
had
a 29% increased incidence|35105006|260366006
of systemic hypertension|38341003
compared
to age-|424144002
and
sex-matched controls.[15]|258139002|33336008|54776003|258139002|33336008|31509003|365952006|33336008|54776003|365952006|33336008|31509003|263495000|33336008|54776003|263495000|33336008|31509003|70256003|33336008|54776003|70256003|33336008|31509003|57312000|33336008|54776003|57312000|33336008|31509003

The major risk factor|255603008|80943009
for most glaucomas,|23986001
and
focus|87017008|363702006
of treatment,|276239002|416118004
is
increased intraocular pressure,|112222000
i.e.|42146005|22971001

ocular hypertension.|4210003

Intraocular pressure|41633001|252832004|370960006
is
a function|246464006
of production
of liquid aqueous humor|33463005|425460003|33463005|280587006|264312008|425460003|264312008|280587006
by the ciliary processes|7345001
of the eye,|81745001|244486005
and
its drainage|307488001|122462000
through the trabecular meshwork.|66731004|280694002

Aqueous humor|425460003|280587006
flows
from the ciliary processes|7345001
into the posterior chamber,|255551008
bounded|75958009|257768005|418131003
posteriorly
by the lens|78076003|181169005
and
the zonules
of Zinn,
and
anteriorly
by the iris.|41296002|27527003|181164000

It then
flows
through the pupil|392406005|35146001
of the iris|41296002|27527003|181164000
into the anterior chamber,|31636006
bounded|75958009|257768005|418131003
posteriorly
by the iris|41296002|27527003|181164000
and
anteriorly
by the cornea.|28726007|181162001

From here,
the trabecular meshwork|66731004|280694002
drains|32712000
aqueous humor|425460003|280587006
via Schlemm's canal|55268005
into scleral plexuses|18619003|264149005
and
general blood circulation.[16]|60132005|87612001|413854007|60132005|119273009|413854007

In open/wide-angle glaucoma,|46168003|90522003|56116003|46168003
flow
is
reduced|260400001
through the trabecular meshwork,|66731004|280694002
due to the degeneration|33359002
and
obstruction|26036001
of the trabecular meshwork,|66731004|280694002
whose original function|19535007|246464006
is
to
absorb
the aqueous humor.|425460003|280587006

Loss
of aqueous humor absorption|425460003|280587006
leads|88488004|236874000
to increased resistance|35105006|30714006|260366006|30714006
and
thus
a chronic, painless buildup|82423001
of pressure|279046003|13543005|257893003
in the eye.|81745001|244486005

[17]
In close/narrow-angle,|29179001|419422001
the iridocorneal angle|48362000
is
completely
closed|29179001
because of forward displacement|255540008|286668001|255540008|263739008|255540008|276626008
of the final roll|42796001
and
root|85077000|2338009
of the iris|41296002|27527003|181164000
against the cornea,|28726007|181162001
resulting|42752001
in the inability
of the aqueous fluid|32457005|33463005|255765007
to flow
from the posterior|255551008
to the anterior chamber|31636006
and
then
out of the trabecular network.|231734003|82736000|20870005

This accumulation
of aqueous humor|425460003|280587006
causes|134198009
an acute increase|272118002|260366006
of pressure|279046003|13543005|257893003
and
pain.|22253000

The inconsistent relationship|260380004|272151006
of glaucomatous optic neuropathy|23986001|77157004
with ocular hypertension|4210003
has
provoked hypotheses|410658008
and
studies|110465008|224699009
on anatomic structure,|91723000
eye development,|81745001|278923009|244486005|278923009
nerve compression trauma,|84116009|84116009
optic nerve blood flow,|18234004|58190003|180938001|58190003
excitatory neurotransmitter,|35069000
trophic factor,|87276001|384759009
retinal ganglion cell/axon degeneration,|95695004|53102003|60436000
glial support cell,|2156000|9096001|2156000|243114000
immune system,|116003000
aging|248280005
mechanisms|257544000
of neuron loss,|47220008
and
severing
of the nerve fibers|88545005
at the scleral edge.[18][19][20][21][22][23][24][25][26][27][28][29]|18619003|57183005|264644001|264657009

Screening|20135006
for glaucoma|23986001
is
usually
performed|398166005
as part|260726005
of a standard eye examination|36228007
performed|398166005
by optometrists,|28229004
orthoptists|159027001
and
ophthalmologists.|422234006

Testing|272393004
for glaucoma|23986001
should
include|55919000
measurements|272391002
of the intraocular pressure|41633001|252832004|370960006
via tonometry,|164729009
changes|243326001|263703002
in size|277049003
or
shape|107644003|246176004|300842002
of the eye,|81745001|244486005
anterior chamber angle examination|48362000|5880005|244498000|5880005
or
gonioscopy,|76949005
and
examination|5880005
of the optic nerve to|18234004|180938001
look|386548000
for any visible damage|24054004|37782003
to it,
or
change|243326001|263703002
in the cup-to-disc ratio|415183006|118586006|428178003|118586006
and
also rim appearance|386548000|255412001
and
vascular change.|59820001|243326001|59820001|263703002

A formal visual field test|246176004|86944008
should
be
performed.|398166005

The retinal nerve fiber layer|5665001|420294002|103067001|420294002
can
be
assessed
with imaging techniques|278395004
such as optical coherence tomography,|392010000
scanning laser polarimetry,|392005004
and/or
scanning laser ophthalmoscopy,|252846004
also
known|36692007
as Heidelberg retina tomography.[30][31]|5665001|371575001|264664006|5665001|77477000|264664006|181171005|371575001|264664006|181171005|77477000|264664006

Owing to the sensitivity|35209006|365705006
of all methods|260686004|272394005
of tonometry|164729009
to corneal thickness,|251691009
methods|260686004|272394005
such as Goldmann tonometry|164729009
should
be
augmented|35105006
with pachymetry to
measure|246445000|272391002
central corneal thickness (CCT).|422162007

A thicker-|246703001
than-average cornea|28726007|181162001
can
result|394617004
in a pressure reading|279046003|50360004|13543005|50360004|257893003|50360004
higher|75540009|371879000
than the 'true' pressure,|31874001|279046003|31874001|13543005|31874001|257893003
whereas
a thinner-|228993002
than-average cornea|28726007|181162001
can
produce
a pressure reading|279046003|50360004|13543005|50360004|257893003|50360004
lower|261122009
than the 'true' pressure.|31874001|279046003|31874001|13543005|31874001|257893003

Because
pressure|279046003|13543005|257893003
measurement error|272391002
can
be
caused|23981006|134198009
by more|242762006
than just CCT
(i.e.,|42146005|22971001
corneal hydration,|28726007|405006006
elastic properties,|370130000|116685008
etc.
)
,
it
is
impossible
to 'adjust' pressure measurements|410617001|279046003|272391002|410617001|13543005|272391002|410617001|257893003|272391002
based|418836005
only
on CCT measurements.|272391002

The frequency doubling illusion|260864003|1305003|5152006|272123002|1305003|5152006
can
also
be
used|394850002
to
detect|260373001
glaucoma|23986001
with the use|277889008|419385000
of a frequency doubling technology perimeter.[32]|392017002

Examination|5880005
for glaucoma also|23986001
could
be
assessed
with more attention|242762006|6769007
given|419582001
to sex,|258139002|365952006|263495000|70256003|57312000
race,|415229000
history|392521001
of drug use,|246488008
refraction,|366060000|252886007
inheritance|246071007
and
family history.[30]|57177007

The United States Preventive Services Task Force|223688001|278032008|223688001|278032008|285653008
as of 2005 states there|398070004
is
insufficient evidence to|71978007|18669006|423437008|18669006
recommend
for
or
against screening|20135006
for glaucoma.|23986001

There
is
thus
no national screening programs|20135006
in the
US.

There
is
in the UK.

Those at risk|410519009
are
advised|424900004
to
have
a dilated eye examination|255381004|36228007
at least
once a year.[37]|258707000|259039008

The modern goals|410518001
of glaucoma management|23986001|413454004|23986001|119270007
are
to
avoid
glaucomatous damage|23986001|37782003
and
nerve damage,|57182000
and
preserve|277405005
visual field|73750009
and
total quality|258755000|263496004|255619001|263496004
of life|224130005
for patients,|116154003
with minimal side effects.|255605001|255604002

This
requires
appropriate diagnostic techniques|103693007
and
follow-up examinations,
and
judicious selection|50606000
of treatments|276239002
for the individual patient.|125676002|116154003|385435006|116154003

Although
intraocular pressure|41633001|252832004|370960006
is
only
one|421379005
of the major risk factors|255603008|80943009
for glaucoma,|23986001
lowering|261122009
it
via various pharmaceuticals|256220008|421967003
and/or
surgical techniques|83578000|272394005
is
currently|15240007
the mainstay
of glaucoma treatment.|386757008

Vascular flow|58190003
and
neurodegenerative theories
of glaucomatous optic neuropathy|23986001|77157004
have
prompted studies|110465008|224699009
on various neuroprotective therapeutic strategies,|256220008|262202000
including|55919000
nutritional compounds,|62105006
some
of which
may
be
regarded
by clinicians
as safe
for use now,|277889008|419385000
while
others|74964007
are
on trial.|110465008

Because of the important role
of the visual system|49549006|281831001
in balance|249982003|78933003|282295000
and
maintaining posture|385630006|363855006
in human beings,|278412004
glaucoma patients|23986001|116154003
should
consider
themselves
at greater risk|263768009|30207005
of falls,|1912002
and
would
be
advised|424900004
to
take|419652001
the necessary precautions to
help
prevent
any accidents.

In addition,|260364009
since
the peripheral visual system|14414005|49549006|14414005|281831001
has
such a high contribution|75540009|371879000
to this intrinsic balancing mechanism,|260521003|249982003|257544000|260521003|282298003|257544000|255406006|249982003|257544000|255406006|282298003|257544000
the severity|272141005
of glaucoma|23986001
and
degree|258395000|246173007
of visual field obstruction|73750009|26036001
should
also
be
considered.

Because of the relationship|272151006
of glaucoma|23986001
with age,|424144002
other associated factors|74964007|47429007
affecting|247591002|248448006
balance|249982003|78933003|282295000
(i.e.|42146005|22971001

impaired proprioception|260379002|40226000
may
also
be
present, further|52101004|46053002|246105001|46053002
increasing|260369004
the risk|30207005
of falls.|1912002

Of interesting note,|225469004
one cohort|421379005
of open-angle glaucoma patients|46168003|116154003
had
their ability to|371150009
maintain|385630006
posture|363855006
measured|258104002
(
via measurements|272391002
of sway
)
in binocular
(two-eyed|420797005|81745001|420797005|244486005
)
and
monocular
(one-eyed,|421379005|81745001|421379005|244486005
using|260676000
both
affected|247591002|248448006
and
unaffected eyes|81745001
)
conditions,|260905004
as well as
with their eyes|81745001
closed.|29179001

These patients|116154003
had
increased sway|35105006|260366006
(worse balance|249985001
)
in their one-eyed conditions|421379005|81745001|260905004|421379005|244486005|260905004
compared
to the two-eyed conditions,|420797005|81745001|260905004|420797005|244486005|260905004
and
reduced sway|260400001
(better balance|3442003|249982003|3442003|78933003|3442003|282295000
)
when
using|260676000
one eye|421379005|81745001|421379005|244486005
than
when
their eyes|81745001
were
closed|29179001
,
but
there
were
no significant differences|386134007|263735002
between the two monocular conditions,|420797005|260905004
with the unaffected eye|81745001|244486005
having
only slightly|50607009|425404009|420295001|425404009
(
but
not significantly
)
reduced sway|260400001
than
when
using|260676000
their affected eyes.|247591002|81745001|248448006|81745001

All patients|116154003
in each condition|260905004
displayed
increased sway|35105006|260366006
compared
to their age-matched controls.[41]|424144002|33336008|54776003|424144002|33336008|31509003

Intraocular pressure|41633001|252832004|370960006
can
be
lowered|261122009|385440003
with medication,|410942007
usually eye drops.|385125006

Several different classes|261028005|263735002|258391009
of medications|410942007
are
used|394850002
to
treat|395077000
glaucoma,|23986001
with several different medications|261028005|263735002|410942007
in each class.|258391009

Each
of these medicines|410942007
may
have
local|255470001
and
systemic side effects.|31099001

Adherence
to medication protocol|410942007|258049002
can
be
confusing|286933003
and
expensive
;
if side effects
occur|272120004
,
the patient|116154003
must
be
willing|225466006
either
to
tolerate
them,
or
to
communicate|288577006
with the treating physician to|28995006|309343006
improve|385425000|3442003|385633008
the drug regimen.|410942007

Initially,|884001
glaucoma drops|23986001|426684005|23986001|404218003
may
reasonably
be
started|385652002
in
either
one|421379005
or
in
both
eyes.[42]|81745001

Poor compliance
with medications|410942007
and
follow-up visits|185389009
is
a major reason|255603008|410666004
for vision loss
in glaucoma patients.|23986001|116154003

A 2003 study|110465008|224699009
of patients|116154003
in an HMO|72311000
found|404684003
half
failed
to
fill
their prescriptions|260885003
the first time,|255216001|410669006|232714002|410669006
and
one-fourth|421379005|29970001
failed
to
refill
their prescriptions|260885003
a second time.|81170007|410669006|257997001|410669006|288495006|410669006

Patient education|311401005
and
communication|263536004
must
be
ongoing|255238004
to
sustain|263892007
successful treatment|182985004
plans|312011006|52713000|397943006
for this lifelong disease|64572001
with no early symptoms.|264499004

The possible neuroprotective effects|371930009|253861007|60022001|253861007
of various topical|256220008|256220008|359540000
and
systemic medications|31099001|410942007
are
also
being
investigated.[6][44][45][46]|116698004

Both
laser|122456005|38586004
and
conventional surgeries|255333006|83578000
are
performed|398166005
to
treat|395077000
glaucoma.|23986001

Surgery|83578000
is
the primary therapy|63161005|276239002|261424001|276239002
for those with congenital glaucoma.|20401003|413728006|421463005|413728006

Generally,
these operations|83578000
are
a temporary solution,|14803004|8537005|14803004|77899000
as
there
is
not yet
a cure
for glaucoma.|23986001

Canaloplasty
is
a nonpenetrating procedure|71388002
using|260676000
microcatheter technology.

To
perform|398166005
a canaloplasty,
an incision|34896006
is
made
into the eye to|81745001|244486005
gain|35105006|255396000|260366006|260369004|398092000
access|260507000
to the Schlemm's canal|55268005
in a similar fashion
to a viscocanalostomy.|312973004

A microcatheter
will
circumnavigate
the canal|3262009|257577001
around the iris,|41296002|27527003|181164000
enlarging|260376009
the main drainage channel|63161005|307488001|255592004|63161005|122462000|255592004
and
its smaller collector|263796003|255507004
channels|255592004
through the injection|28289002|385218009|129326001
of a sterile, gel-|261029002|385100002|15296000|385100002
like material|260769002
called viscoelastic.

The catheter|19923001
is
then
removed|127485006
and
a suture|18557009|408099007|360765007
is
placed|257557008|421066005
within the canal|3262009|257577001
and
tightened.

By opening|56116003
the canal,|3262009|257577001
the pressure|279046003|13543005|257893003
inside the eye|81745001|244486005
may
be
relieved|398004007
,
although
the reason|410666004
is
unclear,
since
the canal|3262009|257577001
(
of Schlemm
)
does
not
have
any significant fluid resistance|386134007|32457005|30714006|386134007|33463005|30714006|386134007|255765007|30714006|386134007|30714006
in glaucoma|23986001
or
healthy eyes.|263775005|81745001

Long-term results|394617004
are
not available.[48][49]|103328004

Argon laser trabeculoplasty (ALT)|404636007
may
be
used|394850002
to
treat|395077000
open-angle glaucoma.|46168003

It
is
a temporary solution,|14803004|8537005|14803004|77899000
not
a cure.

A 50-?m argon laser spot|118311005|23840004
is
aimed
at the trabecular meshwork to|66731004|280694002
stimulate
opening|56116003
of the mesh to|404213007
allow
more outflow|242762006
of aqueous fluid.|32457005|33463005|255765007

Usually,
half
of the angle|1483009
is
treated|28995006
at a time.|410669006

Traditional laser trabeculoplasty|263901007|172485001
uses|277889008|394850002|260676000|419385000
a thermal argon laser|118311005
in an argon laser trabeculoplasty procedure.|404636007|71388002

A newer type|7147002|261664005
of laser trabeculoplasty|172485001
uses|277889008|394850002|260676000|419385000
a "cold"|285686007|82272006|84162001
(nonthermal
)
laser to|122456005|38586004
stimulate
drainage|307488001|122462000
in the trabecular meshwork.|66731004|280694002

This newer procedure,|7147002|71388002
selective laser trabeculoplasty (SLT),|392028003
uses|277889008|394850002|260676000|419385000
a 532-nm,
frequency-doubled,|260864003|1305003|272123002|1305003
Q-switched
Nd:YAG laser,|261344006
which selectively
targets
melanin pigment|59094002|65863008
in the trabecular meshwork cells.|66731004|4421005|280694002|4421005

Studies|110465008|224699009
show
SLT
is
as effective|255403003|254648000
as ALT|56935002
at lowering eye pressure.|261122009|81745001|279046003|261122009|81745001|13543005|261122009|81745001|257893003|261122009|244486005|279046003|261122009|244486005|13543005|261122009|244486005|257893003

In addition,|260364009
SLT
may
be
repeated|27582007
three|421291004
to four times,|421534005|410669006|421534005|417929005
whereas
ALT|56935002
can
usually
be
repeated|27582007
only
once.

Nd:YAG laser peripheral iridotomy (LPI)|371345007
may
be
used|394850002
in patients|116154003
susceptible|131196009
to
or
affected|247591002|248448006
by angle closure glaucoma|392291006
or
pigment dispersion syndrome.|46168003|392133001

During laser iridotomy,|371345007
laser energy|122456005|248272003|38586004|248272003
is
used to|394850002
make
a small, full-thickness opening|255507004|255597005|56116003
in the iris to|41296002|27527003|181164000
equalize
the pressure|279046003|13543005|257893003
between the front|255549009
and
back of the iris,|41296002|27527003|181164000
thus
correcting|370975003
any abnormal bulging|263654008|442672001|263654008|112639008
of the iris.|41296002|27527003|181164000

In people|125676002
with narrow angles,|419422001
this
can
uncover|255368006
the trabecular meshwork.|66731004|280694002

In some cases|398241000|413769002
of intermittent|7087005
or
short-term angle closure,|251726002
this
may
lower|261122009
the eye pressure.|81745001|279046003|81745001|13543005|81745001|257893003|244486005|279046003|244486005|13543005|244486005|257893003

Laser iridotomy|371345007
reduces|260400001
the risk|30207005
of developing
an attack|217315002|216299002
of acute angle closure.|272118002|251726002

In most cases,|398241000|413769002
it also
reduces|260400001
the risk|30207005
of developing chronic angle closure|90734009|251726002
or
of adhesions|42685002
of the iris|41296002|27527003|181164000
to the trabecular meshwork.|66731004|280694002

Diode laser cycloablation|397537003
lowers|261122009
IOP
by reducing aqueous secretion|260400001|46242002
by destroying secretory ciliary epithelium.[30]|46242002|280869000|46242002|280870004

The most common conventional surgery|4757001|72906007|255333006|83578000
performed|398166005
for glaucoma|23986001
is
the trabeculectomy.|231734003

Here,
a partial thickness flap|263835006|256683004
is
made
in the scleral wall|18619003|224727009
of the eye,|81745001|244486005
and
a window opening|224755008|56116003|385673002|56116003
is
made
under the flap to|256683004
remove|127485006
a portion|260726005
of the trabecular meshwork.|66731004|280694002

The scleral flap|18619003|256683004
is
then
sutured loosely|408099007|29684008
back
in place to|257557008|421066005
allow
fluid|32457005|33463005|255765007
to flow
out of the eye|81745001|244486005
through this opening,|56116003
resulting|42752001
in lowered intraocular pressure|19721008
and
the formation|11798007|255277001
of a bleb|408764000
or
fluid bubble|32457005|33463005|255765007
on the surface|410678000
of the eye.|81745001|244486005

Scarring|275322007
can
occur|272120004
around
or
over the flap opening,|256683004|56116003
causing|23981006
it to
become
less effective|276139006|255403003|276139006|254648000|263796003|255403003|263796003|254648000
or
lose
effectiveness altogether.|255403003

Traditionally,
chemotherapeutic adjuvants,|416608005|427067006|367336001|427067006
such as mitomycin C|387331000
(MMC,|387331000
0.5-0.2 mg/ml|258798001
)
or
5-fluorouracil|387172005
(5-FU,|387172005
50 mg/ml|258798001
)
,
are
applied|410618006
with soaked sponges|42691000|106902003|42691000|257264006
on the wound bed to|267036007|229772003|13924000|229772003
prevent
filtering blebs|408764000
from scarring|275322007
by inhibiting fibroblast proliferation.|61511001|52547004|30217000

Contemporary alternatives
include|55919000
the sole|57999000
or
combinative implementation
of nonchemotherapeutic adjuvants,|427067006
such as collagen matrix implant[50][51][52][53]|386929009
or
other biodegradable spacers,|74964007|243135003
to
prevent
super scarring|275322007
by randomization
and
modulation
of fibroblast proliferation|52547004|30217000
in addition|260364009
to the mechanical prevention|261018001|169443000
of wound contraction|267036007|78558002|13924000|78558002
and
adhesion.|42685002

Professor Anthony Molteno
developed
the first glaucoma drainage implant,|255216001|370943001|232714002|370943001
in Cape Town|228230007|288521009
in 1966.

Since then,
several different types|261028005|263735002|261664005
of implants|40388003
have
followed|367409002
on
from the original,|19535007
the Baerveldt tube shunt,|410447006
or
the valved implants,|40388003
such as the Ahmed glaucoma valve implant|410446002|23986001|40388003|410446002|23986001|71861002|410446002|23986001|64218007
or
the
ExPress
Mini Shunt|262445005|442119001|262445005|257351008|262445005|125319009
and
the later generation pressure ridge Molteno implants.|260383002|279046003|26833005|360120008|260383002|13543005|26833005|360120008|260383002|257893003|26833005|360120008

These
are
indicated|410535002
for glaucoma patients|23986001|116154003
not
responding
to maximal medical therapy,|56851009|243121000|398303009|243121000
with previous failed guarded filtering surgery|9130008|116250002|83578000|9130008|258648006|83578000
(trabeculectomy|231734003
).

The flow tube|83059008
is
inserted|257867005
into the anterior chamber|31636006
of the eye,|81745001|244486005
and
the plate|271003
is
implanted|40388003
underneath the conjunctiva to|29445007|181161008
allow
flow
of aqueous fluid|32457005|33463005|255765007
out of the eye|81745001|244486005
into a chamber
called
a bleb.|408764000

The ongoing scarring|255238004|255238004|275322007
over the conjunctival dissipation segment|29445007|264193005
of the shunt|442119001|257351008|125319009
may
become
too thick|246703001
for the aqueous humor to|425460003|280587006
filter|116250002|258648006
through.

This
may
require
preventive measures|262073000|246445000|262073000|367346004|129428001|246445000|129428001|367346004
using|260676000
antifibrotic medications,|410942007
such as 5-fluorouracil|387172005
or
mitomycin-C|387331000
(
during the procedure|71388002
)
,
or
other nonantifibrotic medication methods,|272394005|410942007
such as collagen matrix implant,|386929009
[56][57] biodegradable spacer,|243135003
or
additional surgery.|260364009|83578000

And
for glaucomatous painful blind eye|23986001|225569001
and
some cases|398241000|413769002
of glaucoma,|23986001
cyclocryotherapy|71091006
for ciliary body ablation|416100002
could
be
considered
to
be
performed.[30]|398166005

TR BioSurgical
has
commercialized
a new implant specifically|7147002|40388003|7147002|71861002|7147002|64218007
for veterinary medicine,|53216000|410942007
called TR-ClarifEYE.

The implant|40388003|71861002|64218007
consists
of a new biomaterial,|7147002
the STAR BioMaterial,|437997008
which
consists
of silicone|13652007
with a very precise homogenous pore size,|260358002|22061001|277049003
a property|370130000
which
reduces|260400001
fibrosis|263756000
and
improves|385425000|3442003|385633008
tissue integration.|85756007

The implant|40388003|71861002|64218007
contains|42504009
no valves
and
is
placed completely|257557008|421066005
within the eye|81745001|244486005
without sutures.|408099007|360765007

To date,|410671006
it
has
demonstrated long-term success|385669000
(longer|255511005
than a year|258707000|259039008
)
in a pilot study|308040008|110465008|308040008|224699009
in medically refractory dogs|20646008|448771007|20646008
with advanced glaucoma.[58]|86005002|23986001

The most common surgical approach currently|4757001|72906007|424876005|15240007
used|394850002
for the treatment|276239002|416118004
of glaucoma|23986001
is
trabeculectomy,|231734003
in which
the sclera|18619003|181163006
is
punctured to|11639007
alleviate
intraocular pressure.|41633001|252832004|370960006

Nonpenetrating deep sclerectomy (NPDS) surgery|413954006|83578000
is
a similar,
but
modified, procedure,|71388002|243326001|71388002
in which
instead of puncturing|11639007|85921004
the scleral wall,|18619003|224727009
a patch|1522000|262302002|385114002|386028003|413676000|421043009
of the sclera|18619003|181163006
is
skimmed
to a level,|258395000|276625007
upon which,
percolation
of liquid|33463005|264312008
from the inner eye|260521003|81745001|260521003|244486005
is
achieved
and
thus
alleviating
intraocular pressure,|41633001|252832004|370960006
without penetrating|53568006
the eye.|81745001|244486005

NPDS
is
demonstrated to
cause|23981006|134198009
significantly fewer side effects
than trabeculectomy._[citation|231734003
needed|410525008|103325001
_] However,
NPDS
is
performed manually|398166005
and
requires
great skill._[citation|255509001|263768009
needed|410525008|103325001
_]

Laser-assisted NPDS|122456005|371152001|38586004|371152001
is
performed|398166005
with the use|277889008|419385000
of a CO2 laser system.|118312003|246333005

The laser-based system|122456005|246333005|122456005|418836005|246333005|38586004|246333005|38586004|418836005|246333005
is
self-terminating|58322009
once the required scleral thickness|18619003|246703001
and
adequate drainage|51117008|307488001|51117008|122462000|88323005|307488001|88323005|122462000
of the intraocular fluid|425460003
have
been
achieved.

This self-regulation effect|253861007
is
achieved
as the CO2 laser essentially|118312003
stops|260890000
ablating|127485006
as soon
as it
comes
in contact|52101004|11723008|52101004|70862002|18720000|11723008|18720000|70862002
with the intraocular percolated liquid,|33463005|264312008
which
occurs|272120004
as soon
as the laser|122456005|38586004
reaches|282679008
the optimal residual intact layer thickness.|65320000|11163003|246703001

Natural compounds|510009|62105006
of research interest|225469004
in glaucoma prevention|23986001|169443000
or
treatment|276239002|416118004
include|55919000
:
fish oil|346441008
and
omega-3 fatty acids,|226365003
alpha lipoic acid,|70496003
[60] bilberries,|227417005
vitamin E,|37237003
cannabinoids,|421921003
carnitine,|59888006|372601001
coenzyme Q10,|412129003
curcurmin,
_Salvia miltiorrhiza_,|67757005
dark chocolate,|255419005|102262009
erythropoietin,|83042003|43979001
folic acid,|63718003|104660009
_Ginkgo biloba_,|7182001|420733007
ginseng,|412395006
L-glutathione,|258995007|423272009|258995007|63399009|420559008|423272009|420559008|63399009
grape seed extract,|256317002|264337003|62972009
green tea,|412194001
magnesium,|72717003
melatonin,|41199001|121256005
methylcobalamin,|259512006
N-acetyl-L cysteine,|387440002
pycnogenols,
resveratrol,|96383001
quercetin|52130006
and
salt.|387390002

However,
most
of these compounds|62105006
have
not demonstrated effectiveness|255403003
in clinical trials.|110465008

Magnesium,|72717003
ginkgo,|64199006|7182001|420733007
salt|387390002
and
fludrocortisone,|116586002
are
already
used|394850002
by some physicians.|309343006

(Note
:
fludrocortisone|116586002
is
not
a natural compound,|510009|62105006
but
a steroid.|116566001
)

Studies|110465008|224699009
in the 1970s
showed
marijuana,|398705004|228998006|10083006
when
smoked|64197008|102407002|365981007
or
eaten, effectively|48263008
lowers|261122009
intraocular pressure|41633001|252832004|370960006
by about 25%,
as
much
as standard medications.|410942007

In an effort to|19487008
determine
whether marijuana,|398705004|228998006|10083006
or
drugs|410942007
derived
from it,
might
be
effective|255403003|254648000
as a glaucoma treatment,|386757008
the
US National Eye Institute supported research studies|81745001|385437003|9096001|110465008|81745001|385437003|9096001|224699009|81745001|385437003|243114000|110465008|81745001|385437003|243114000|224699009|244486005|385437003|9096001|110465008|244486005|385437003|9096001|224699009|244486005|385437003|243114000|110465008|244486005|385437003|243114000|224699009
from 1978
to 1984.

These studies|110465008|224699009
demonstrated
some derivatives
of marijuana|398705004|228998006|10083006
lowered|261122009|385440003
intraocular pressure|41633001|252832004|370960006
when
administered|418283001
orally,|260548002
intravenously,
or
by smoking,|365981007
but
not
when
topically
applied|410618006
to the eye.|81745001|244486005

In 2003,
the American Academy
of Ophthalmology|394594003
released|68776005|129299003
a position statement|246449006
which
said|66049007
,
"studies|110465008|224699009
demonstrated
that
some derivatives
of marijuana|398705004|228998006|10083006
did
result|394617004
in lowering|261122009
of IOP
when
administered|418283001
orally,|260548002
intravenously,
or
by smoking,|365981007
but
not
when
topically
applied|410618006
to the eye.|81745001|244486005

The duration|103335007
of the pressure-lowering effect|279046003|261122009|253861007|13543005|261122009|253861007|257893003|261122009|253861007
is
reported to|229059009|223458004
be
in the range
of 3|260313008
to 4 hours".[63][64]|123031003

However,
the position paper|246449006|50833004
qualified
that statement
by stating marijuana|398070004|398070004|398705004|398070004|228998006|398070004|10083006
was
not more effective|255403003|254648000
than prescription medications,|260885003|410942007
and
"
no scientific evidence|18669006
has
been
found|404684003
that
demonstrates
increased benefits|35105006|260366006
and/or
diminished risks|1250004|30207005
of marijuana|398705004|228998006|10083006
use|277889008|419385000
to
treat|395077000
glaucoma|23986001
compared
with the wide variety|90522003
of pharmaceutical agents|421967003|260872001
now available|103328004
."

The first patient|255216001|116154003|232714002|116154003
in the United States federal government's Compassionate Investigational New Drug program,|223688001|386053000|7147002|410942007
Robert Randall,
was
afflicted
with glaucoma|23986001
and
had
successfully fought charges|248005005
of marijuana cultivation|398705004|228998006|10083006
because
it
was
deemed
a medical necessity|74188005
(_[U.S.|223688001

v.

Randall]
(/w/index.php?title|419205000
=U.S._|223688001
v.
_Randall&action|129264002
=edit&redlink
=1|260305007
)
_
)
in 1976.[65]|264695004

Peripherally selective 5-HT2A agonists,|102498003
such as the indazole derivative AL-34662,|422102009
are
currently|15240007
under development|278923009
and
show
significant promise|386134007
in the treatment|276239002|416118004
of glaucoma.[66][67]|23986001

The world's smallest computer system,|263796003|246333005|255507004|246333005
one millimeter square|421379005|258673006|56924007
in size,|277049003
has
been
developed
by researchers
at the University of Michigan,|224871002|224067004
and
is
designed to
be
implanted|40388003
in a person's eye|125676002|81745001|125676002|244486005
as a pressure monitor to continuously|279046003|13288007|13543005|13288007|257893003|13288007
track|257719005
the progress|385651009
of glaucoma.|23986001

The processor
consists
of an ultra-low-power microprocessor,|13740005
a pressure sensor,|397645001
memory,|303116000|106136008
a thin-film battery,|18043004|65053001|18043004|50084004
a solar cell,|49926000|4421005|49926000|362837007
and
a wireless radio|360004001
with an antenna
that
can
transmit|60117003
data
to an external reader device.[68]|261074009|303607000|264697007|261074009|49062001|264697007

The survey team
of Dr.|309343006
Yoshiki Sasai,
[69] working|264698002|261041009
at the RIKEN
of Center|26216008
for Developmental Biology|278923009|12893009
(CDB
in Japan,|223583001
succeeded
in making
a retina cell|5665001|4421005|5665001|362837007|181171005|4421005|181171005|362837007
in three dimensions|264672008
from embryonic stem cells,|419965008
as
was
reported|229059009|223458004
in _Nature_|277302009
(7 April 2011
).

It
was
the first|255216001|232714002
such success|385669000
in the world,
and
Dr.|309343006

Sasai
said|66049007
the goal|410518001
for putting
it
to practical use|277889008|419385000
in the retinas|5665001
of human|278412004
for clinical applications|58147004|410618006
was
within two years.|420797005|258707000

Glaucoma|23986001
has
been
classified|73504009
into specific types|69658003|261664005
:
[71]|264699005

Primary glaucoma|63161005|23986001|261424001|23986001

Variants|40885006
of primary glaucoma|63161005|23986001|261424001|23986001

*
*Primary angle closure glaucoma|392291006|392288006
*
*
is
caused|23981006|134198009
by contact|11723008|70862002
between the iris|41296002|27527003|181164000
and
trabecular meshwork,|66731004|280694002
which in turn|282987006
obstructs|263821009
outflow
of the aqueous humor|425460003|280587006
from the eye.|81745001|244486005

This contact|11723008|70862002
between iris|41296002|27527003|181164000
and
trabecular meshwork (TM)|66731004|280694002
may
gradually
damage|37782003
the function|246464006
of the meshwork
until
it
fails
to
keep
pace
with aqueous production,
and
the pressure rises.|279046003|13543005|257893003

In over half|21481007
of all cases,|398241000|413769002
prolonged contact|255224006|11723008|255224006|70862002
between iris|41296002|27527003|181164000
and
TM
causes|134198009
the formation|11798007|255277001
of synechiae|78778007
(effectively "
scars|70582006|275322007
"
).

These cause permanent obstruction|134198009|6934004|26036001
of aqueous outflow.

In some cases,|398241000|413769002
pressure|279046003|13543005|257893003
may
rapidly build up|418694008|255532002|418694008|353734004
in the eye,|81745001|244486005
causing|23981006
pain|22253000
and
redness|386713009|371240000
(symptomatic,|264931009
or
so called "acute" angle closure|223528007|272118002|251726002
).

In this situation,
the vision|281004000
may
become
blurred,|246636008
and
halos|83551002
may
be
seen
around bright lights.|221668007|56242006

Accompanying symptoms
may
include|55919000
headache|25064002
and
vomiting.|249497008

Diagnosis|439401001
is
made
from physical signs|72670004
and
symptoms
:
pupils|392406005
mid-dilated|255562008|255381004
and
unresponsive|20646008|422768004
to light,|56242006|371268001
cornea edematous|27194006
(cloudy|81858005
)
,
reduced vision,|397540003
redness,|386713009|371240000
and
pain.|22253000

However,
the majority
of cases|398241000|413769002
are
asymptomatic.|84387000

Prior to very severe loss|260358002|24484000
of vision,|281004000
these cases|398241000|413769002
can
only
be
identified|7882003
by examination,|5880005
generally
by an eye care|225363004
professional.

Once any symptoms
have
been
controlled|31509003
,
the first line|255216001|50009006|232714002|50009006
(
and
often definitive|70232002|261002007
)
treatment|276239002|416118004
is
laser iridotomy.|371345007

This
may
be
performed|398166005
using|260676000
either
Nd
:
YAG
or
argon lasers,|118311005
or
in some cases|398241000|413769002
by conventional incisional surgery.|255333006|34896006|83578000

The goal|410518001
of treatment|276239002|416118004
is
to
reverse
,
and
prevent
,
contact|11723008|70862002
between iris|41296002|27527003|181164000
and
trabecular meshwork.|66731004|280694002

In early to moderately advanced cases,|264499004|86005002|398241000|264499004|86005002|413769002
iridotomy|108147006|386607008
is
successful|385669000
in opening|56116003
the angle|1483009
in
around 75%
of cases.|398241000|413769002

In the other 25%,|74964007
laser iridoplasty,|424830006
medication|410942007
(pilocarpine|372895002
)
or
incisional surgery|34896006|83578000
may
be
required.

*
*Primary open-angle glaucoma|77075001
*
*
is
when
optic nerve damage results|18234004|37782003|394617004|180938001|37782003|394617004|81745001|57182000|394617004
in a progressive loss|255314001
of the visual field.|73750009

This
is
associated|47429007
with increased pressure|51590001
in the eye.|81745001|244486005

Not
all people|125676002
with primary open-angle glaucoma|77075001
have
eye|81745001|244486005
pressure|279046003|13543005|257893003
that
is
elevated|75540009
beyond normal,|17621005|258744000
but
decreasing|260371004
the eye|81745001|244486005
pressure|279046003|13543005|257893003
further|46053002
has
been
shown
to
stop|422117008
progression even|246453008|246450006
in these cases.|398241000|413769002

The increased pressure|51590001
is
caused|23981006|134198009
by trabecular blockage.|231734003|82736000|20870005

Because
the microscopic passageways|84496004|255592004
are
blocked|26036001|112232007
,
the pressure builds|279046003|13543005|257893003
up
in the eye|81745001|244486005
and
causes|134198009
imperceptible very gradual vision loss.|260358002|255343009

Peripheral vision|77944008
is
affected first,|247591002|255216001|247591002|232714002|248448006|255216001|248448006|232714002
but
eventually
the entire vision|255503000|281004000|260232004|281004000
will
be
lost
if
not
treated.|28995006

Diagnosis|439401001
is
made
by looking|386548000
for cupping|231097002
of the optic nerve.|18234004|180938001

Prostaglandin agonists|26351002|102498003
work|261041009
by opening uveoscleral passageways.|56116003|255592004

Beta blockers,|373254001
such as timolol,|372880004
work|261041009
by decreasing aqueous formation.|260371004|11798007|260371004|255277001

Carbonic anhydrase inhibitors|372816000
decrease|260400001|260370003
bicarbonate formation|68615006|11798007|68615006|255277001
from ciliary processes|7345001
in the eye,|81745001|244486005
thus
decreasing|260371004
formation|11798007|255277001
of Aqueous humor.|425460003|280587006

Parasympathetic analogs
are
drugs|410942007
that
work|261041009
on the trabecular outflow|231734003|82736000|20870005
by opening|56116003
up the passageway|255592004
and
constricting|410719006
the pupil.|392406005|35146001

Alpha 2 agonists|372548005
(brimonidine,|372547000
apraclonidine|391786008
both
decrease fluid production|260400001|32457005|260400001|33463005|260400001|255765007|260400001|260370003|32457005|260370003|33463005|260370003|255765007|260370003
(
via.

inhibition|61511001|419495008
of AC
)
and
increase drainage.|260366006|307488001|260366006|122462000

Developmental glaucoma|413728006

Secondary glaucoma|95717004

*
*Neovascular glaucoma|232086000
*
*,
an uncommon type|103356009|261664005
of glaucoma,|23986001
is
difficult|52925006
or
nearly impossible to
treat|395077000
,
and
is
often|70232002
caused|23981006|134198009
by proliferative diabetic retinopathy (PDR)|59276001
or
central retinal vein occlusion (CRVO).|68478007

It
may
also
be
triggered|410658008
by other conditions|74964007|260905004
that result|394617004
in ischemia|52674009
of the retina|5665001|181171005
or
ciliary body.|29534007|263340007

Individuals|125676002|385435006
with poor blood flow|11403006|58190003|255351007|58190003
to the eye|81745001|244486005
are
highly at risk|75540009|30207005
for this condition.|260905004

Neovascular glaucoma results|232086000|394617004
when
new, abnormal vessels|7147002|263654008|59820001
begin|255395001
developing
in the angle|1483009
of the eye|81745001|244486005
that
begin|255395001
blocking|2899008|112232007
the drainage.|307488001|122462000

Patients|116154003
with such condition|260905004
begin|255395001
to rapidly|418694008
lose
their eyesight.

Sometimes,
the disease|64572001
appears
very rapidly,|260358002|418694008
especially after cataract surgery procedures.|47337003|83578000

A new treatment|7147002|276239002|7147002|416118004
for this disease,|64572001
as
first
reported|229059009|223458004
by Kahook
and
colleagues,
involves|248448006
use|277889008|419385000
of a novel group|7147002|261586004|7147002|160481000|7147002|389109008
of medications|410942007
known|36692007
as anti-VEGF agents.|255635008

These injectable medications|385218009|410942007|129326001|410942007
can
lead|88488004
to a dramatic decrease|260400001|260370003
in new vessel formation|7147002|59820001|11798007|7147002|59820001|255277001
and
,
if
injected|422145002
early|264499004
enough
in the disease process,|64572001|415178003
may
lead|88488004
to normalization
of intraocular pressure.|41633001|252832004|370960006

*
*Toxic glaucoma|23986001
*
*
is
open angle glaucoma|46168003
with an unexplained significant rise|386134007
of intraocular pressure|41633001|252832004|370960006
following|255260001
unknown pathogenesis.|261665006|303109001

Intraocular pressure|41633001|252832004|370960006
can
sometimes
reach|282679008
80 mmHg|304621005
(11 kPa|259017006
).

It characteristically
manifests|250255003
as ciliary body inflammation|29534007|257552002|263340007|257552002
and
massive trabecular oedema|49731008|231734003|49731008|82736000|49731008|20870005
that sometimes
extends|255590007
to Schlemm's canal.|55268005

This condition|260905004
is
differentiated|263933003
from malignant glaucoma|10100008
by the presence|386397008
of a deep|131197000
and
clear anterior chamber|263707001|31636006
and
a lack|41277001
of aqueous misdirection.

Also,
the corneal appearance|28726007|386548000|28726007|255412001
is
not
as
hazy.

A reduction|58294000|260400001|289928003
in visual acuity|363983007
can
occur|272120004
followed neuroretinal breakdown.|367409002|40091007|367409002|125366008

Associated factors|47429007
include|55919000
inflammation,|257552002
drugs,|410942007
trauma
and
intraocular surgery,|83578000
including|55919000
cataract surgery|54885007|422349000|110473004
and
vitrectomy procedures.|75732000

Gede Pardianto
(2005
)
reported|229059009|223458004
on four patients|421534005|116154003
who
had
toxic glaucoma.|23986001

One|421379005
of them
underwent
phaecoemulsification
with small particle nucleus drops.|255507004|84640000|426684005|255507004|84640000|404218003

Some cases|398241000|413769002
can
be
resolved
with some medication,|410942007
vitrectomy procedures|75732000
or
trabeculectomy.|231734003

Valving
procedures|71388002
can
give|419582001
some relief,|224978009
but
further research|46053002
is
required.[73]

Absolute glaucoma|19144002
is
the end stage|42796001
of all types|261664005
of glaucoma.|23986001

The eye|81745001|244486005
has
no vision,|281004000
absence|2667000|418560003
of pupillary light reflex|40137007|400921004
and
pupillary response,|392406005
and
has
a stony appearance.|384600008|386548000|384600008|255412001

Severe pain|76948002
is
present|52101004|246105001
in the eye.|81745001|244486005

The treatment|276239002|416118004
of absolute glaucoma|19144002
is
a destructive procedure|64597002
like cyclocryoapplication,
cyclophotocoagulation,|35137007
or
injection|28289002|385218009|129326001
of 100% alcohol.|419442005|53041004|430837008

M
:
EYE|81745001|244486005

anat(g/a/p/phys/devp/prot|258795003|304383000

noco/cong/tumr,
epon

proc,
drug|410942007
(S1A/1E/1F/1L

